Literature DB >> 20631411

Regulation of cAMP by phosphodiesterases in erythrocytes.

Shaquria P Adderley1, Randy S Sprague, Alan H Stephenson, Madelyn S Hanson.   

Abstract

The erythrocyte, a cell responsible for carrying and delivering oxygen in the body, has often been regarded as simply a vehicle for the circulation of hemoglobin. However, it has become evident that this cell also participates in the regulation of vascular caliber in the microcirculation via release of the potent vasodilator, adenosine triphosphate (ATP). The regulated release of ATP from erythrocytes occurs via a defined signaling pathway and requires increases in cyclic 3',5'- adenosine monophosphate (cAMP). It is well recognized that cAMP is a critical second messenger in diverse signaling pathways. In all cells increases in cAMP are localized and regulated by the activity of phosphodiesterases (PDEs). In erythrocytes activation of either beta adrenergic receptors (beta(2)AR) or the prostacyclin receptor (IPR) results in increases in cAMP and ATP release. Receptor-mediated increases in cAMP are tightly regulated by distinct PDEs associated with each signaling pathway as shown by the finding that selective inhibitors of the PDEs localized to each pathway potentiate both increases in cAMP and ATP release. Here we review the profile of PDEs identified in erythrocytes, their association with specific signaling pathways and their role in the regulation of ATP release from these cells. Understanding the contribution of PDEs to the control of ATP release from erythrocytes identifies this cell as a potential target for the development of drugs for the treatment of vascular disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20631411      PMCID: PMC2922877          DOI: 10.1016/s1734-1140(10)70303-0

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  79 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.

Authors:  Claire Lugnier
Journal:  Pharmacol Ther       Date:  2005-08-15       Impact factor: 12.310

Review 2.  Compartmentation of cyclic nucleotide signaling in the heart: the role of A-kinase anchoring proteins.

Authors:  Kimberly L Dodge-Kafka; Lorene Langeberg; John D Scott
Journal:  Circ Res       Date:  2006-04-28       Impact factor: 17.367

Review 3.  Functional localization of cAMP signalling in cardiac myocytes.

Authors:  G Vandecasteele; F Rochais; A Abi-Gerges; R Fischmeister
Journal:  Biochem Soc Trans       Date:  2006-08       Impact factor: 5.407

4.  A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes.

Authors:  Francesca Rochais; Aniella Abi-Gerges; Kathleen Horner; Florence Lefebvre; Dermot M F Cooper; Marco Conti; Rodolphe Fischmeister; Grégoire Vandecasteele
Journal:  Circ Res       Date:  2006-03-23       Impact factor: 17.367

5.  Rabbit erythrocytes possess adenylyl cyclase type II that is activated by the heterotrimeric G proteins Gs and Gi.

Authors:  Randy Sprague; Elizabeth Bowles; Madelyn Stumpf; Gregory Ricketts; Alberto Freidman; Wei-Hsien Hou; Alan Stephenson; Andrew Lonigro
Journal:  Pharmacol Rep       Date:  2005       Impact factor: 3.024

6.  An anchored PKA and PDE4 complex regulates subplasmalemmal cAMP dynamics.

Authors:  Debbie Willoughby; Wei Wong; Jerome Schaack; John D Scott; Dermot M F Cooper
Journal:  EMBO J       Date:  2006-04-27       Impact factor: 11.598

Review 7.  Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use.

Authors:  Andrew T Bender; Joseph A Beavo
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 8.  Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.

Authors:  Anna R Hemnes; Hunter C Champion
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-05

Review 9.  Restricted diffusion of a freely diffusible second messenger: mechanisms underlying compartmentalized cAMP signalling.

Authors:  M Zaccolo; G Di Benedetto; V Lissandron; L Mancuso; A Terrin; I Zamparo
Journal:  Biochem Soc Trans       Date:  2006-08       Impact factor: 5.407

10.  Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway.

Authors:  Marco Mongillo; Carlo G Tocchetti; Anna Terrin; Valentina Lissandron; York-Fong Cheung; Wolfgang R Dostmann; Tullio Pozzan; David A Kass; Nazareno Paolocci; Miles D Houslay; Manuela Zaccolo
Journal:  Circ Res       Date:  2005-12-15       Impact factor: 17.367

View more
  15 in total

Review 1.  Erythrocyte-derived ATP and perfusion distribution: role of intracellular and intercellular communication.

Authors:  Randy S Sprague; Mary L Ellsworth
Journal:  Microcirculation       Date:  2012-07       Impact factor: 2.628

Review 2.  Regulation of blood flow distribution in skeletal muscle: role of erythrocyte-released ATP.

Authors:  Mary L Ellsworth; Randy S Sprague
Journal:  J Physiol       Date:  2012-05-14       Impact factor: 5.182

3.  AKAP-dependent modulation of BCAM/Lu adhesion on normal and sickle cell disease RBCs revealed by force nanoscopy.

Authors:  Jamie L Maciaszek; Biree Andemariam; Krithika Abiraman; George Lykotrafitis
Journal:  Biophys J       Date:  2014-03-18       Impact factor: 4.033

Review 4.  Purinergic control of red blood cell metabolism: novel strategies to improve red cell storage quality.

Authors:  Kaiqi Sun; Angelo D'alessandro; Yang Xia
Journal:  Blood Transfus       Date:  2017-04-12       Impact factor: 3.443

5.  Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension.

Authors:  Elizabeth A Bowles; Gina N Moody; Yashaswini Yeragunta; Alan H Stephenson; Mary L Ellsworth; Randy S Sprague
Journal:  Exp Biol Med (Maywood)       Date:  2014-08-14

6.  Hydroxycarbamide decreases sickle reticulocyte adhesion to resting endothelium by inhibiting endothelial lutheran/basal cell adhesion molecule (Lu/BCAM) through phosphodiesterase 4A activation.

Authors:  Vicky Chaar; Sandrine Laurance; Claudine Lapoumeroulie; Sylvie Cochet; Maria De Grandis; Yves Colin; Jacques Elion; Caroline Le Van Kim; Wassim El Nemer
Journal:  J Biol Chem       Date:  2014-03-10       Impact factor: 5.157

7.  A selective phosphodiesterase 3 inhibitor rescues low PO2-induced ATP release from erythrocytes of humans with type 2 diabetes: implication for vascular control.

Authors:  Randy S Sprague; Elizabeth A Bowles; David Achilleus; Alan H Stephenson; Christopher G Ellis; Mary L Ellsworth
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-09-30       Impact factor: 4.733

Review 8.  Alteration of purinergic signaling in diabetes: Focus on vascular function.

Authors:  Rui Zhou; Xitong Dang; Randy S Sprague; S Jamal Mustafa; Zhichao Zhou
Journal:  J Mol Cell Cardiol       Date:  2020-02-11       Impact factor: 5.000

9.  Reduced deformability contributes to impaired deoxygenation-induced ATP release from red blood cells of older adult humans.

Authors:  Matthew L Racine; Frank A Dinenno
Journal:  J Physiol       Date:  2019-07-27       Impact factor: 5.182

Review 10.  Blood cells: an historical account of the roles of purinergic signalling.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2015-08-11       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.